Neuroepithelial Stem Cells: The many roles of C1q
The ability of C1q to bind to a variety of receptors has implications for signaling biology, spinal cord injury and, possibly, the evolution of the complement system.
- Department of Biomedical Genetics, University of Rochester School of Medicine and Dentistry, United States
The protein C1q is best known for its role in the immune system: as a part of the C1 complex of the complement cascade, it helps to clear microbes and cellular debris from the body. However, it also has other roles beyond the immune system: for example, working with other elements of the complement cascade it helps to eliminate immature synapses during development of the visual system (Stevens et al., 2007) and is involved in Wnt signaling in muscle cells (Naito et al., 2012). C1q can also bind to myelin-associated glycoprotein and mask its ability to inhibit neurite outgrowth (Peterson et al., 2015), while the loss of C1q in mice results in cognitive decline (Stephan et al., 2013). More recent studies suggest a role for C1q in neurodegeneration (reviewed in Cho, 2019).
Now, in eLife, Francisca Benavente (University of California Irvine and Universidad del Desarrollo), Aileen Anderson (UC Irvine) and colleagues report new roles for C1q that have intriguing implications for signaling biology, recovery from spinal cord injury, stem cell-based therapies and, possibly, the evolution of the complement system (Benavente et al., 2020). The work shows that C1q is a ligand that can bind directly to several previously unidentified receptors (CD44, GPR62, BAI1, c-MET, and ADCY5), triggering the activation of downstream signaling pathways. The researchers demonstrate that in doing so, C1q can modulate different aspects of the biology of neuroepithelial stem cells (NSCs). Specifically, they show that C1q promotes the migration of NSCs by binding to a cell-surface glycoprotein called CD44, while promoting NSC proliferation via interactions with G-protein coupled receptor signaling pathways.
CD44 knockout eliminates the ability of C1q to promote chemotaxis, but not the ability to promote division, in NSCs. Likewise, the effects of C1q on NSC differentiation appear to be independent of signaling via CD44. Nonetheless, C1q also exhibited a dose-dependent effect on NSC differentiation: while a low nM dose significantly increased the generation of Olig-2+ oligodendrocyte-lineage cells in wild-type NSCs, fewer Olig-2+ cells were seen with higher concentrations of C1q in both wild-type and CD44 knock-out cells. A similar inhibitory effect was observed on the differentiation of two other cell types (GFAP+ astroglia and ßIII-tubulin expressing neuronal lineage cells), which also appeared to be independent of signaling via CD44.
Benavente et al. also demonstrate that C1q, again acting via CD44, has important effects on the ability of transplanted NSCs to promote recovery from spinal cord injury. Previously they had shown that delayed transplantation into a rodent model of spinal cord injury was associated with the migration of cells away from the injury epicenter, differentiation of the NSCs mostly into oligodendrocytes, and improved motor function (Salazar et al., 2010; Hooshmand et al., 2017). In contrast, transplantation right after the injury was associated with increased migration towards the epicenter, differentiation mostly into astroglial cells, and no effects on motor recovery. Now, they have found that the genetic inhibition of CD44 in NSCs, or the use of antibodies to inhibit C1q, prevented clustering of transplanted NSCs in the injury epicenter, reduced astroglial differentiation, and significantly improved motor outcomes when NSCs were transplanted into mice immediately after injury. They also found elevated levels of C1q in the injury epicenter following spinal cord injury, which suggests that this pathway has a role in the response to the injury.
The latest work also raises a number of interesting questions. Would inhibiting inflammation increase the utility of NSC transplantation in spinal cord injury? Does the efficacy of delayed transplantation depend upon decreased inflammation and C1q production in the injury site by this time? Moreover, the binding of C1q to other NSC receptor proteins (including two G-protein coupled receptors and the receptor tyrosine kinase c-Met) suggests that C1q may modulate a complex array of effects on NSC behavior within the injury site.
One would also like to know if the latest results are relevant to recovery in areas of the central nervous system where NSCs still exist in adults, and whether there are effects of age-related increases in C1q on these NSC compartments. Moreover, CD44 is expressed in many different cell types, and its expression changes dramatically during injury: are other cells susceptible to C1q-mediated effects on chemotaxis via CD44? Also, if the normal expression of C1q in an injury site is to promote the migration of cells that might be important in repair, would decreasing the inflammatory response be counterproductive in some instances? It would also be interesting to explore the effects of C1q on cell function more generally.
The observations that C1q is a ligand for multiple receptors may also lead to a better understanding of the evolution of the complement system. The evolutionary value of a single protein that works as a component of a multi-protein complex is difficult to discern. However, if C1q started off as a signaling ligand, its evolution is easier to understand. In addition, one wonders whether other components of the complement cascade might also have additional roles outside of their immunological functions.
Regardless of the answers to these questions, the discovery that C1q is itself a ligand for multiple receptors, and is capable of modulating important NSC functions, opens up a new window for studying the biology of C1q that is sure to lead to a series of provocative further discoveries.
References
-
Emerging roles of complement protein C1q in neurodegenerationAging and Disease 10:652–663.https://doi.org/10.14336/AD.2019.0118
-
Neutrophils induce astroglial differentiation and migration of human neural stem cells via C1q and C3a synthesisThe Journal of Immunology 199:1069–1085.https://doi.org/10.4049/jimmunol.1600064
-
A dramatic increase of C1q protein in the CNS during normal agingJournal of Neuroscience 33:13460–13474.https://doi.org/10.1523/JNEUROSCI.1333-13.2013
Article and author information
Author details
Publication history
- Version of Record published: September 14, 2020 (version 1)
Copyright
© 2020, Noble and Pröschel
This article is distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use and redistribution provided that the original author and source are credited.
Metrics
-
- 996
- views
-
- 105
- downloads
-
- 2
- citations
Views, downloads and citations are aggregated across all versions of this paper published by eLife.
Download links
A two-part list of links to download the article, or parts of the article, in various formats.
Downloads (link to download the article as PDF)
Open citations (links to open the citations from this article in various online reference manager services)
Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)
Neuroepithelial Stem Cells: The many roles of C1q
eLife 9:e61599.
https://doi.org/10.7554/eLife.61599
Further reading
-
- Biochemistry and Chemical Biology
- Stem Cells and Regenerative Medicine
Molecules that facilitate targeted protein degradation (TPD) offer great promise as novel therapeutics. The human hepatic lectin asialoglycoprotein receptor (ASGR) is selectively expressed on hepatocytes. We have previously engineered an anti-ASGR1 antibody-mutant RSPO2 (RSPO2RA) fusion protein (called SWEETS) to drive tissue-specific degradation of ZNRF3/RNF43 E3 ubiquitin ligases, which achieved hepatocyte-specific enhanced Wnt signaling, proliferation, and restored liver function in mouse models, and an antibody–RSPO2RA fusion molecule is currently in human clinical trials. In the current study, we identified two new ASGR1- and ASGR1/2-specific antibodies, 8M24 and 8G8. High-resolution crystal structures of ASGR1:8M24 and ASGR2:8G8 complexes revealed that these antibodies bind to distinct epitopes on opposing sides of ASGR, away from the substrate-binding site. Both antibodies enhanced Wnt activity when assembled as SWEETS molecules with RSPO2RA through specific effects sequestering E3 ligases. In addition, 8M24-RSPO2RA and 8G8-RSPO2RA efficiently downregulate ASGR1 through TPD mechanisms. These results demonstrate the possibility of combining different therapeutic effects and degradation mechanisms in a single molecule.
-
- Developmental Biology
- Stem Cells and Regenerative Medicine
Endothelial and skeletal muscle lineages arise from common embryonic progenitors. Despite their shared developmental origin, adult endothelial cells (ECs) and muscle stem cells (MuSCs) (satellite cells) have been thought to possess distinct gene signatures and signaling pathways. Here we shift this paradigm by uncovering how adult MuSC behavior is affected by the expression of a subset of EC transcripts. We used several computational analyses including single-cell RNAseq to show that MuSCs express low levels of canonical EC markers in mice. We demonstrate that MuSC survival is regulated by one such prototypic endothelial signaling pathway (VEGFA-FLT1). Using pharmacological and genetic gain- and loss-of-function studies, we identify the FLT1-AKT1 axis as the key effector underlying VEGFA-mediated regulation of MuSC survival. All together, our data support that the VEGFA-FLT1-AKT1 pathway promotes MuSC survival during muscle regeneration, and highlights how the minor expression of select transcripts is sufficient for affecting cell behavior.
